Charged particle and conventional radiotherapy: current implications as partner for immunotherapy
Radiotherapy (RT) has been shown to interfere with inflammatory signals and to enhance tumor immunogenicity via, e.g., immunogenic cell death, thereby potentially augmenting the therapeutic efficacy of immunotherapy. Conventional RT consists predominantly of high energy photon beams. Hypofractionate...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23 March 2021
|
| In: |
Cancers
Year: 2021, Volume: 13, Issue: 6, Pages: 1-29 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13061468 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers13061468 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/13/6/1468 
|
| Author Notes: | Damiënne Marcus, Relinde I.Y. Lieverse, Carmen Klein, Amir Abdollahi, Philippe Lambin, Ludwig J. Dubois and Ala Yaromina |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1760886580 | ||
| 003 | DE-627 | ||
| 005 | 20220819235305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210619s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13061468 |2 doi | |
| 035 | |a (DE-627)1760886580 | ||
| 035 | |a (DE-599)KXP1760886580 | ||
| 035 | |a (OCoLC)1341416687 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Marcus, Damiënne |e VerfasserIn |0 (DE-588)1235792978 |0 (DE-627)1760886564 |4 aut | |
| 245 | 1 | 0 | |a Charged particle and conventional radiotherapy |b current implications as partner for immunotherapy |c Damiënne Marcus, Relinde I.Y. Lieverse, Carmen Klein, Amir Abdollahi, Philippe Lambin, Ludwig J. Dubois and Ala Yaromina |
| 264 | 1 | |c 23 March 2021 | |
| 300 | |a 29 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.06.2021 | ||
| 520 | |a Radiotherapy (RT) has been shown to interfere with inflammatory signals and to enhance tumor immunogenicity via, e.g., immunogenic cell death, thereby potentially augmenting the therapeutic efficacy of immunotherapy. Conventional RT consists predominantly of high energy photon beams. Hypofractionated RT regimens administered, e.g., by stereotactic body radiation therapy (SBRT), are increasingly investigated in combination with cancer immunotherapy within clinical trials. Despite intensive preclinical studies, the optimal dose per fraction and dose schemes for elaboration of RT induced immunogenic potential remain inconclusive. Compared to the scenario of combined immune checkpoint inhibition (ICI) and RT, multimodal therapies utilizing other immunotherapy principles such as adoptive transfer of immune cells, vaccination strategies, targeted immune-cytokines and agonists are underrepresented in both preclinical and clinical settings. Despite the clinical success of ICI and RT combination, e.g., prolonging overall survival in locally advanced lung cancer, curative outcomes are still not achieved for most cancer entities studied. Charged particle RT (PRT) has gained interest as it may enhance tumor immunogenicity compared to conventional RT due to its unique biological and physical properties. However, whether PRT in combination with immune therapy will elicit superior antitumor effects both locally and systemically needs to be further investigated. In this review, the immunological effects of RT in the tumor microenvironment are summarized to understand their implications for immunotherapy combinations. Attention will be given to the various immunotherapeutic interventions that have been co-administered with RT so far. Furthermore, the theoretical basis and first evidences supporting a favorable immunogenicity profile of PRT will be examined. | ||
| 650 | 4 | |a carbon ion | |
| 650 | 4 | |a charged particle radiation | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a proton | |
| 650 | 4 | |a radiotherapy | |
| 700 | 1 | |a Lieverse, Relinde I. Y. |e VerfasserIn |0 (DE-588)1217818383 |0 (DE-627)1733239472 |4 aut | |
| 700 | 1 | |a Klein, Carmen |d 1989- |e VerfasserIn |0 (DE-588)1203165900 |0 (DE-627)1687982678 |4 aut | |
| 700 | 1 | |a Abdollahi, Amir |e VerfasserIn |0 (DE-588)129612715 |0 (DE-627)474757765 |0 (DE-576)297748874 |4 aut | |
| 700 | 1 | |a Lambin, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dubois, Ludwig J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yaromina, Ala |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 6, Special issue, Artikel-ID 1468, Seite 1-29 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Charged particle and conventional radiotherapy current implications as partner for immunotherapy |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:6 |g supplement:Special issue |g elocationid:1468 |g pages:1-29 |g extent:29 |a Charged particle and conventional radiotherapy current implications as partner for immunotherapy |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13061468 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/6/1468 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210619 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 129612715 |a Abdollahi, Amir |m 129612715:Abdollahi, Amir |d 910000 |d 911400 |e 910000PA129612715 |e 911400PA129612715 |k 0/910000/ |k 1/910000/911400/ |p 4 | ||
| 998 | |g 1203165900 |a Klein, Carmen |m 1203165900:Klein, Carmen |p 3 | ||
| 999 | |a KXP-PPN1760886580 |e 3939730106 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"29 S."}],"id":{"eki":["1760886580"],"doi":["10.3390/cancers13061468"]},"language":["eng"],"recId":"1760886580","person":[{"family":"Marcus","display":"Marcus, Damiënne","roleDisplay":"VerfasserIn","given":"Damiënne","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Lieverse","display":"Lieverse, Relinde I. Y.","role":"aut","given":"Relinde I. Y."},{"display":"Klein, Carmen","family":"Klein","roleDisplay":"VerfasserIn","role":"aut","given":"Carmen"},{"role":"aut","given":"Amir","display":"Abdollahi, Amir","family":"Abdollahi","roleDisplay":"VerfasserIn"},{"family":"Lambin","display":"Lambin, Philippe","roleDisplay":"VerfasserIn","given":"Philippe","role":"aut"},{"given":"Ludwig J.","role":"aut","family":"Dubois","display":"Dubois, Ludwig J.","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Ala","roleDisplay":"VerfasserIn","family":"Yaromina","display":"Yaromina, Ala"}],"title":[{"subtitle":"current implications as partner for immunotherapy","title":"Charged particle and conventional radiotherapy","title_sort":"Charged particle and conventional radiotherapy"}],"note":["Gesehen am 19.06.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"23 March 2021","dateIssuedKey":"2021"}],"relHost":[{"pubHistory":["1.2009 -"],"disp":"Charged particle and conventional radiotherapy current implications as partner for immunotherapyCancers","origin":[{"publisherPlace":"Basel","dateIssuedKey":"2009","publisher":"MDPI","dateIssuedDisp":"2009-"}],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"part":{"year":"2021","text":"13(2021), 6, Special issue, Artikel-ID 1468, Seite 1-29","extent":"29","issue":"6","volume":"13","pages":"1-29"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["614095670"],"issn":["2072-6694"],"zdb":["2527080-1"]},"language":["eng"],"recId":"614095670","title":[{"title":"Cancers","title_sort":"Cancers"}],"note":["Gesehen am 27.05.2020"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"name":{"displayForm":["Damiënne Marcus, Relinde I.Y. Lieverse, Carmen Klein, Amir Abdollahi, Philippe Lambin, Ludwig J. Dubois and Ala Yaromina"]}} | ||
| SRT | |a MARCUSDAMICHARGEDPAR2320 | ||